CD38‐Targeted Theranostics of Lymphoma with 89 Zr/ 177 Lu‐Labeled Daratumumab
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD38‐Targeted Theranostics of Lymphoma with
89
Zr/
177
Lu‐Labeled Daratumumab
Authors
Keywords
-
Journal
Advanced Science
Volume 8, Issue 10, Pages 2001879
Publisher
Wiley
Online
2021-03-15
DOI
10.1002/advs.202001879
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
- (2020) Ilaria Saltarella et al. Cells
- ImmunoPET: Concept, Design, and Applications
- (2020) Weijun Wei et al. CHEMICAL REVIEWS
- Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
- (2019) Ruben S. A. Goedegebuure et al. Frontiers in Immunology
- Combining immunotherapy and radiotherapy for the STAR treatment
- (2019) Jordan A. Torok et al. Nature Reviews Clinical Oncology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials
- (2018) Loredana Marcu et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab
- (2018) Lei Kang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Effective weight control via an implanted self-powered vagus nerve stimulation device
- (2018) Guang Yao et al. Nature Communications
- Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
- (2017) Emily B. Ehlerding et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radioimmunoconjugates for treating cancer: recent advances and current opportunities
- (2017) Mickaël Bourgeois et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
- (2016) Larysa Sanchez et al. Journal of Hematology & Oncology
- Preclinical Pharmacokinetics and Biodistribution Studies of 89 Zr-Labeled Pembrolizumab
- (2016) Christopher G. England et al. JOURNAL OF NUCLEAR MEDICINE
- Advances in Peptide Receptor Radionuclide Therapy
- (2016) Amir Sabet et al. SEMINARS IN NUCLEAR MEDICINE
- Synthesis and Preclinical Evaluation of177Lu-CHX-A”-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma
- (2015) Mythili Kameswaran et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
- (2015) Kristoff Muylle et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Targeted Radionuclide Therapy of Human Tumors
- (2015) Sergey Gudkov et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
- (2013) D. J. Green et al. CANCER RESEARCH
- A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
- (2009) J. R. Berenson et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now